156
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      Drug repurposing for paediatric oncology indications: overview of possible approaches and illustration of a case study

      Published
      conference-abstract
      Bookmark

            Abstract

            Children are receiving only a fraction of the advances in new adult cancer treatments. Whilst cancer survival rates for children have improved significantly over the last 20 years, for some specific cancers we have not seen a substantial improvement in cure rates over the same time period. Over the past 30 years only 6 new drugs have been approved specifically for use in paediatric cancer. There is a clear lack of incentives to support the development of specific childhood cancer drugs. In this context, drug repurposing strategies are well suited to deliver tangible benefits to paediatric cancer patients. Several examples of drug repurposing in the field of paediatric oncology/haematology, using different scientific strategies, are highlighted. More recently artificial intelligence/machine learning-powered approaches have been earning ground and one such case is presented here more in detail.

            Neuroblastoma (NB) is a type of cancer that develops from immature nerve cells and subset of neuroblastoma patients has a relatively high rate of relapse and becomes refractory to treatment. There is an urgent need for new therapies to address this medical need. We aimed at the identification and validation or approved drugs that may be able to treat high risk NB in children, accelerating children’s access to new drugs and reduce the cost of the development process.

            An Artificial Intelligence (AI) approach based on Disease-Gene Expression Matching (DGEM) was used to identify drug repurposing candidates. In silico analysis identified 12 already approved drugs that were further tested in vitro using patient-derived cell lines and organoids, and in vivo with NB PDX mice. Four of these compounds exhibited anti-proliferative activity and were selected for further characterization. We screened combinations of two classes of drugs and observed high synergistic effects and a substantial decrease in neuroblastoma cell viability. Combination treatment resulted in the upregulation of pathways linked to neuron projection development, metabolism of lipids, vesicle-mediated transport, and autophagy regulation. Additionally, the combination resulted in a phenotypic switch to a more chemosensitive cell state. In vitro pretreatment with the combinations confirmed the sensitization of patient-derived NB organoids to cisplatin. Preliminary In vivo experiments further support these findings.

            This projects represent an example of how AI-driven approaches, combined with advanced in vitro/in vivo testing capabilities may lead to the rapid and cost-effective identification of drug repurposing candidates for rare diseases that are not prioritized by the pharma industry.

            Content

            Author and article information

            Conference
            REPO4EU
            4 October 2023
            Affiliations
            [1 ] aPODD Foundation, London (United Kingdom);
            [2 ] Division of Translational Cancer Research, Lund University, Lund, Sweden ( https://ror.org/012a77v79)
            [3 ] Healx Ltd., Cambridge (United Kingdom);
            Article
            10.58647/REXPO.23016
            ae9c0a0e-febb-4810-9469-7a08d542b53e
            Authors

            Published under Creative Commons Attribution 4.0 International ( CC BY 4.0). Users are allowed to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source.

            RExPO23
            2
            Stockholm, Sweden
            25-26 October 2023
            History
            Product

            REPO4EU

            Categories

            Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
            Pharmacology & Pharmaceutical medicine
            Drug Repurposing,Paediatric Oncology,Neuroblastoma,Artificial Intelligence,Machine Learning,Gene Expression,in vitro/ in vivo

            References

            1. Laetsch Theodore W., DuBois Steven G., Bender Julia Glade, Macy Margaret E., Moreno Lucas. Opportunities and Challenges in Drug Development for Pediatric Cancers. Cancer Discovery. Vol. 11(3):545–559. 2021. American Association for Cancer Research (AACR). [Cross Ref]

            2. Tranfaglia Michael R., Thibodeaux Clare, Mason Daniel J., Brown David, Roberts Ian, Smith Richard, Guilliams Tim, Cogram Patricia. Repurposing available drugs for neurodevelopmental disorders: The fragile X experience. Neuropharmacology. Vol. 147:74–86. 2019. Elsevier BV. [Cross Ref]

            Comments

            Comment on this article